Hello Jean – trust all goes well.
Although the volume is light at present I’m giving consideration to it is imperative that the short position keep this down as far as possible (Stating the obvious) as news could hit any time now.
I will be very interested to see the next short report and needless to say I shall be more than pleased to get confirmation of the anticipated patent victory.
Best regards and best wishes to all longs.
Holding on with both hands ;-)
Interesting ditty for the future, hopefully some thing will come of it.
Although the possibilities are some way off, I noted that our PM picked up on it.
Obviously Dementia will become a greater world wide problem as time goes by. Our system health care expenditure is approximately 75% government funded. It is well reconised that as the population life expectancy extends so will the cost of care. Forward thinking will hopefully ensure that good care is available as far as possible.
Sorry to hear about your farther, having a farther in law suffering with Dementia I know to some extent what you have been through.
My very best regards.
While the board is not so busy, thank you for continuing with the patent challenge information.
Just you to let you know I read most of them if not all.
Good morning Wekillshorts.
Daily Mail 10/03/14
A simple blood test has been developed that gives healthy elderly people precious early warning they may get Alzheimer’s within the next three years.
It is hoped the test, the first to predict accurately who will become ill, could speed the search for new drugs that can delay or even prevent the devastating brain disease.
It could eventually lead to widespread screening in middle-age to identify those most at risk and give them greater warning.
Alzheimer’s and other forms of dementia affect some 800,000 Britons and the number is predicted to double in a generation as the population ages.
Prime Minister David Cameron has described dementia as ‘the key health challenge of this generation’.
Existing medicines are of limited use and several promising pills and potions have failed to live up to hopes.
The latest research, from Georgetown University in Washington DC, opens up the possibility of identifying those who will benefit from them the most
Even delaying the onset of Alzheimer’s would have a massive impact on the lives of sufferers and their loved ones.
Hello Traderalph and Onlyfacts.
Thank you for digging a little further into the subject matter, some very interesting points and information being raised by you both.
Being based in the UK naturally I have a keen interest in developments and the different approaches to moving forward in Europe. Once again the subject matter IMO plays a part of in relation to partnering in Europe. One extract from the original article reminds me of this “ Nuedexta provides the advantage of already being FDA approved, which may help Avanir speed up the development process for alternative indications”. As mentioned previously the EMA has the variation route where as the reference drug can have additional indications added with not so much red tape ie using part of the reference drug data.
Extract of Multi-therapy Drugs Opportunities for Generics & Biosimilars, article.
While regulatory challenges remain in the arena, the need for effective healthcare will continue to rise as the population ages and governments will increasingly look at ways to cut costs. For those companies that are successful in developing generic or biosimilar versions therapies, the financial rewards will undoubtedly be worthwhile. It is small wonder that major players in the innovative industry, like Merck & Co, are beginning to show their hands by openly forging alliances for biosimilar development.
Once again thank you for the additional info.
Never a dull moment here my friend.
Another interesting week, on several fronts. Nice little tussle mid week, once again reminding me that that we are not alone when it comes to holding on with both hands.
Thank you for the weekly round up.
Very best regards.
Hi Frank - Trust all is well.
Like Antartica, while you away ever thing was put on ice ;-)
Many thanks for your kind remarks.
Have a very pleasant weekend.
Hi Onlyfacts thank you for the additional information, I agree I also have not seen any reference regarding agitation from them.
I hope you get to see this reply I really would like to bring to your attention this years 8th World Congress on Controversies in Neurology (CONy) which is taking place in Berlin, Germany, on May 8-11, 2014. I have put a youtube introductory link below. But I would like you to track down the web site by putting the 8th World…. into your browser. As in the past Comtel will issue web casts of the event usually 6 weeks later. Once you get to the web site you will see this years listed topics, many of them are relative to what we have hear including migraine. One example of the debates is listed below. I would say we will learn from the event.
Example of this years debate’s.
Debate: Antipsychotics should not be prescribed in dementia patients
Very best regards.
Good morning Nomargin – you are more than welcome.
PS. Nuedexta is becoming more known in Germany.
Have a pleasant day.
Shift Central The Marketing Intelligence Agency Article by Samantha Both
Large market awaits drug makers developing dementia-specific medications.
In the U.S., more than 21% of dementia patients are treated with antipsychotic medication. This represents a large market share for antipsychotic manufacturers, but can be problematic for marketing if the antipsychotic in question has not been FDA-approved for dementia patients. (J&J Fined 2.2b)
Currently, there are two drugs in the pipeline that stand to gain a potentially large share of the antipsychotic market in dementia patients. Unlike antipsychotics, which are prescribed off-label to dementia patients, these drugs, if approved, will specifically address psychological and behavioral issues in dementia patients.
Acadia's pimavanserin is currently in phase ll for Alzheimer's disease psychosis. The drug has already been shown to be effective for Parkinson’s disease psychosis so positive results are likely in Alzheimer’s.
Avanir's Nuedexta could also capture a share of the antipsychotics-in-dementia market. Nuedexta is the only FDA-approved drug for pseudobulbar affect. The drug (AVP-923) is being studied in several dose strengths for agitation inAlzheimer’s disease.
In June 2012, the FDA accepted an IND for this indication. Nuedexta provides the advantage of already being FDA approved, which may help Avanir speed up the development process for alternative indications.
Although antipsychotic prescribing in dementia is a long-running trend, both pimavanserin and Nuedexta have the potential to shake up the market if approved. The trick will be for Acadia and Avanir to convince physicians to break habit and switch to their drugs. It's likely that antipsychotic use in dementia will continue, but the pharmaceutical companies currently benefiting may see their market share decrease with the introduction of new drugs such as Nuedexta and pimavanserin.
Part 2 of 2
The classic mistake long-term investors make is to panic following a sharp drop in price and sell. Then, when the stock market rebounds, they buy back in. However, the odds are extremely high that the spooked investor will sell low and buy high - not a winning strategy.
There is a market saying that long-term investors should only care about the daily price of a stock on the day they buy and the day they sell. In between those two events, long-term investors should ignore daily stock prices.
The qualifier for this cliche is it applies only under certain conditions:
• If you don't need to sell (to pay for retirement expenses, for example) for five or more years.
• If the whole market is rising or falling, a stock's price will likely go along with the tide even if there is nothing that suggests any problem with the company.
• If your stock is experiencing sharp swings, but the stock market is not, you may want to re-look at the stock to see if anything has fundamentally changed with the company or its market.
• If you need to cash out of a stock as part of a financial plan (retirement, college expenses, and so on), you should pay attention to the daily price changes and plot your exit well in advance. This is why you need a five-year window, to give you the time to pick your exit rather than waiting until the last minute and taking whatever the market gives you for a price.
Long-term investors should not be frightened by daily price changes, but they should not be blind to changes in a stock's price that suggests the company has fundamentally changed and may not offer the future benefits you anticipated.
The first and most important thing you need to know is that for long-term investors, a stock's price is not the same as what the stock is worth.
For the long-term investor, a stock's worth is the potential for growth, dividends and so on. It answers the question: What would you pay today to benefit from the future earnings and associated growth in share price?
This brings us to the second answer to the question about what the price per share tells investors. During the regular buying and selling of the daily market, a stock's per share price tells you where buyers and sellers agree.
For example, if the price of a stock is $25 per share this tells you that there are buyers willing to pay $25 per share and sellers willing to sell for $25 per share. This is a simple explanation of a complicated process that can see this balance recalculated many times each minute the stock exchange is open.
For people who trade stocks, that is frequently buy and sell in an attempt to profit from price changes, there is little concern about long-term prospects for a stock. They are focused on the supply and demand balance and attempt to anticipate changes that may cause prices rise or fall.
When the stock market is especially volatile, investors can become very nervous. A sharp rise or drop in the stock market will often lift or lower prices for most stocks. This movement can be a reflection of the market's concern about current events or future economic conditions that may hinder or help business.
Margin is a line of credit given to an investor so that they may make investments in amounts larger than their current funds would allow. This allows investors the ability to leverage their current holdings and make larger investments hoping that the return will be larger than the interest of the loan. These investors are taking on a larger amount of risk and so are the firms that loan the funds. Because of this most firms deem stocks under 5 to be unmarginable. This means that they will not extend their line of credit on investments under 5. Some set the mark higher or lower but 5 is most common..
Good morning All.
We looked at this before lets see what is next, good to see the 5
Why is the 5 dollar level so important ? and Why will Yahoo not let me post the article extracts, there are no hyper links as I have re typed it word for word. I shall try some bits after this post, failing that those that do not already know about the topic could look up “Why is the 5 dollar level so important”
Have a good day.
I have not seen the Bid have such a relentless gradual stab at it in a good while.
Cowen and Company 34th Annual Health Care Conference
March 3, 2014 - March 5, 2014
“We believe that drugs being developed in CNS going forward will be multi model mechanism like this”